DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Ombrabulin is an investigational drug.
There have been 11 clinical trials for Ombrabulin. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2008.
The most common disease conditions in clinical trials are Neoplasms, Sarcoma, and Ovarian Neoplasms. The leading clinical trial sponsors are Sanofi and [disabled in preview].
Recent Clinical Trials for Ombrabulin
|Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel||Sanofi||Phase 2|
|Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer||Sanofi||Phase 2|
|A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors||Sanofi||Phase 1|